Feature | Published:

The business of making vaccines

Subjects

With a growing need for better and more plentiful vaccines, traditional vaccine companies are responding by increasing manufacturing capacity, the biotech industry, with innovative products. Both are surely needed.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Scherer F.M. American Anti-Trust Institute Working Paper 04-03 29 (American Anti-Trust Institute, Washington, DC, October 2004). http://www.antitrustinstitute.org/recent2/351.pdf

  2. 2

    Datamonitor. Commercial Perspectives: Vaccines (Datamonitor, London, January 2004).

  3. 3

    Ulmer J.B. et al. Heterologous protection against influenza by infection of DNA encoding a viral protein. Science 259, 1691–1692 (1993).

Download references

Author information

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

About this article

Further reading

Figure 1: Estimated current worldwide flu vaccine manufacturing capacity (300 million doses).